Your Source for Venture Capital and Private Equity Financings

Venture Capital News: IgGenix Announces First Close of $40M Series B

2023-02-06
SOUTH SAN FRANCISCO, CA, IgGenix, Inc., a pre-clinical biotechnology company, announced its first close on a $40M Series B financing.
IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease, announced its first close on a $40M Series B financing to advance its lead program in peanut allergy to the clinic. The funding round was led by Alexandria Venture Investments and includes new investor Eli Lilly and Company, as well as existing investors Khosla Ventures, Sean Parker, AllerFund and others.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors